Skip to main content

AIM ImmunoTech Inc. (AIM)

Sector
Healthcare
Industry
Biotechnology
Last price
$0.14
As of

Kresmion compiles this page from AIM's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

AIM ImmunoTech Inc. (AIM): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-12.

As of . Source: SEC EDGAR filings for AIM. Method and limitations.

COMPANY DOSSIER

See the full AIM dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for AIM on one page. Preview it with sample data, then open it live with a free account.

Preview the AIM dossier

Active events for AIM

  • mediumEarnings below estimates

    Q3-2026: Missed consensus by 54.0%, EPS $-0.21 vs $-0.1364 estimate

  • mediumEarnings below estimates

    Q2-2026: Missed consensus by 150.4%, EPS $-0.43 vs $-0.1717 estimate

  • mediumEarnings above estimates

    Q2-2025: Beat consensus by 54.5% - EPS $-3.67632 vs $-8.0719 estimate

  • mediumEarnings below estimates

    Q3-2025: Missed consensus by 59.4% - EPS $-1.56843 vs $-0.9838 estimate

  • mediumEarnings below estimates

    Q4-2025: Missed consensus by 47.9% - EPS $-1.44 vs $-0.9737 estimate

FREE, NO ACCOUNT

Every event on AIM, as it fires

You are seeing 5 of 6 events recorded on AIM since 2026-06-16.

The five above landed across 3 days. The other 1 were recorded on those same days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

No non-option holdings from tracked managers in this reporting quarter.

Recent SEC filings, AIM

More data on AIM

AIM against its peers

AIM's operating margin of -13254.5% ranks in the 29th percentile of 11 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-04-30.

MetricAIMPeer medianPercentilen
Revenue FY88000 USD1.2M USD4613
Operating margin-13254.5%-398.8%2911
Net margin-15861.4%-465.4%2911
Return on equityn/a-194.0%n/a19
1 year-89.5%-59.8%1819

Peers (21): KPRX, XCUR, SNTI, CRIS, IMRN, CSCIF, TCRT, ALZN, ACXP, LGVN, CNSP, VTGN, ZEOX, BGMS, ENSC, APRE, PCSA, JAGX, TPST, CDIO, TOVX. Left out: ENVB (no annual filing), FBLG (no annual filing), CUBT (no annual filing), ADAPY (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (AIM: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Cite this data

Kresmion counts the managers it follows that reported a non-option position in AIM on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on AIM in the last 180 days.

Upstream: SEC EDGAR filings for AIM

Kresmion, "AIM ImmunoTech Inc. (AIM) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/AIM. Upstream data: SEC EDGAR filings for AIM.

Link to this data (HTML):

<a href="https://kresmion.com/research/AIM">AIM ImmunoTech Inc. (AIM) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow AIM on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to AIM for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the AIM dossier
Share

The AIM intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.